Katherine R. Tuttle, MD, FASN, FACP, FNKF, is Executive Director for Research at Providence Inland Northwest Health and Professor of Medicine at the University of Washington. Dr. Tuttle earned her medical degree and completed her residency in Internal Medicine at Northwestern University. She was a fellow in Metabolism and Endocrinology at Washington University, followed by Nephrology fellowship training at the University of Texas Health Science Center, San Antonio.

Dr. Tuttle’s major research interests are in chronic kidney disease (CKD) and cardiovascular-kidney-metabolic (CKM) syndrome. As a clinical and translational scientist, her seminal work in mechanistic and pre-clinical studies laid a foundation for advancing CKM therapies. Over more than three decades, she led studies that delivered SGLT2 inhibitors and GLP-1 receptor agonists as novel agents to reduce risks of kidney failure, major adverse cardiovascular events, and premature mortality. She has also been a lead investigator for other CKM therapies, including next generation incretin, anti-inflammatory, and aldosterone agents. Additionally, she leads the CURE-CKD Registry with >7 million health system patients.

Dr. Tuttle served on the inaugural Board of Directors for the Kidney Health Initiative and chaired the Diabetic Kidney Disease Collaborative, both for the American Society of Nephrology. She has also chaired many initiatives for the National Institutes of Health, the International Society of Nephrology, Kidney Disease Improving Global Outcomes, the National Kidney Foundation, and the American Diabetes Association. Dr. Tuttle has received many honors and awards including the John P. Peters Lifetime Achievement Award from the American Society of Nephrology, the Medal of Excellence from the American Association of Kidney Patients, the Garabed Eknoyan Award from the National Kidney Foundation, the YWCA Woman of Achievement Award in Science, and two University of Washington School of Medicine Outstanding Clinical Faculty Awards. She is an elected member of the American Association of Physicians.

Bullet point descriptions:

• Dr. Tuttle’s research focus is on unraveling disease mechanisms through rigorous preclinical and human mechanistic studies as a basis for translating new CKM therapies into clinical trials and daily practice.

• Over more than three decades, she led studies that delivered breakthrough therapies including SGLT2 inhibitors and GLP-1 receptor agonists to reduce risks of kidney failure, cardiovascular events, and premature mortality.